Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Apogee Therapeutics Inc. (APGE:NASDAQ), powered by AI.
Apogee Therapeutics Inc. is currently trading at $88.33. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Apogee Therapeutics Inc. on Alpha Lenz.
View Apogee Therapeutics Inc.'s valuation metrics on Alpha Lenz.
“Apogee Therapeutics Inc.'s ROE is -31.6%. Explore profitability and growth together.”
Ask for details →Apogee Therapeutics Inc. is a biotechnology company focused on the development of biologic therapies for atopic dermatitis and other inflammatory diseases. The primary purpose of Apogee Therapeutics is to leverage its expertise in immunology and protein engineering to address unmet needs in the treatment of autoimmune and inflammatory conditions. The company is active in sectors such as healthcare and pharmaceuticals, contributing to advancements in medical biotechnology. Apogee Therapeutics plays a significant role in the financial market by advancing cutting-edge therapies in the biopharmaceutical landscape. It engages in research and development efforts to bring innovative biologic medicines to patients, thereby impacting the broader pharmaceutical industry. The company's focus on treating inflammatory diseases aligns with an increasing demand for novel treatments arising from a greater understanding of disease mechanisms and patient needs. By developing specialized biologic solutions, Apogee Therapeutics positions itself as a key player in addressing some of the challenges associated with chronic inflammatory conditions, ultimately pushing forward the boundaries of therapeutic options available to patients worldwide.
“Apogee Therapeutics Inc.'s ROE is -31.6%. Explore profitability and growth together.”
Ask for details →Apogee Therapeutics Inc. (ticker: APGE) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 196 employees.
The current price is $88.33 with a P/E ratio of -x and P/B of -x.
ROE is -31.57%.